THE PHARMA OUTLOOK 2015

Compiled and Delivered by,

Mr. Namdeo G. ShindeAssistant Professor,

Satara College of Pharmacy, Satara (MS) India 415004.ﾠ 12 August 2015.

Johnson and Johnson

Novartis

Roche

Pfizer

Sanofi

Merck

GlaxoSmithKline

Gilead sciences

Teva

Amgen

AbbVie

Eli lilly

Bristol Mayers

Astrazeneka, Bayer

WORLD TOP 15 PHARMACEUTICAL COMPANIES

Top brands in the world

RANK BRAND NAME

GENERIC NAME

SALE2014 COMPANY USE APPROVAL

1 Abilify Aripiprazole +2.23% Bristol Mayers Psychosis 2002

2 Humira adalimumab +3.86% AbbVie Crohns, Rhematoid arthritis

2002

3 Nexium Esmoprazole +0.74% Astrazeneka GI disorder 2000

4 Crestor Rosuvastatin +4.53% Astrazeneka Cholesterol 2002

5 Enbrel Etanercept +1.46% Amgen Rhematoid 1998

How Is The Patent Cliff Affecting The Drug Industry?

Pfizer's Lipitor, an anticholesterol that was the world's top selling drug for eight years, lost market protection at the end of 2011.

In 2012, its sales ranking dropped to 14th, a nearly 61% decline in one year from $12.9 billion to $5.1 billion 2011

Bristol Myers and Sanofi's Plavix, a blood thinner, number 2 in sales in

2012 at $9.5 billion, dropped to number 12 the next year, to

$5.2 billion.

GLOBAL COUNTRY RANKINGS

Coverage and payment policies that value innovative medicinesStrong science based regulatory system

IP rights and its enforcements in US and abroadCompetitive corporate tax rates

Govt. & Private funding of R&D and emerging biopharmaceutical companiesFavourable technology transfer environment

Strong R&D workforce

Favourable trade policy environment

Key points for favourable business operating environment in US

Established in 1983 by Dilip ShanghviSun Pharmaceuticals operates in more than 150 countries across the world.

In the year 2014, Sun Pharmaceuticals acquired Ranbaxy

Laboratories Limited and became the largest pharmaceutical

company in India and the fifth largest pharmaceutical company in

the world.

1968, Lupin is one of the fastest growing Growth rate more than 20%

A January 2014 study, by economists Robert Shapiro and Aparna Mathur, predicted that

‘India could well become a global centre for innovative drug development and production, increase the life expectancy of its people, expand output and employment, and achieve considerable cost savings in medical care and government subsidies’ by increasing its IP protection.

A stronger IP environment will certainly have a positive impact on the Indian economy and

encourage Foreign Direct Investment

Stronger IP rights:

As per 'Pharma Vision 2020', the Government of India aims to make India a global leader in end to end drug manufacturing

Manufacturing costs in India is low than US due to low installation and manufacturing costs

Pharmaceutical exports from India have grown at a CAGR of 21 % over the last decade

Indian vaccines are exported to 150 countries

Currently, Indian drugs are exported to more than 200 countries inthe world, with the US as the key market.

India is home to 10,500 manufacturing units and over 3,000 pharma companies.

Higher spending on R&D, owing to products patents have made

India a major destination for generic drug manufacturing

India's pharma exports stood at US$ 15 billion in 2013-14

India ranks fourth in terms of the total pharma market share in the Asia Pacific

Approximately 70 % of the patients in developing countries receive Indian

medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates

Foundation, Doctors Without Borders, the UNCTAD etc

Gujarat clocked the highest growth rate in pharmaceuticals market at 22.4 % during November

2014.

CLINICAL TRIALSDue to cost advantage India is increasingly becoming a hub for clinical trials.

Due to genetically diverse population and availability of skilled doctors

HEALTH INSURENCE

Penetration of health insurance is expected to cover more than 650 million peoples by 2020.

RSBY, JJBY

‘We want to believe that the Govt. will fulfill its promise’

“MAKE IN INDIA”‘Make, Develop and Innovate in India’

Retail Market